Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study

Status Completed

Clinical Trial Summary

The purpose of the study is to determine if the dose of contrast (Omnipaque) administered for Computed Tomography Arteriograms (CTA) can be reduced without degradation of image quality. The hypothesis is that there is no difference in image quality using ultra-low dose contrast in CTA exams compared to routine, standard of care dose exams.

Clinical Trial Description

Any adult patient age 18 and above, scheduled for routine CTA (Computed Tomography Arteriograms) of the chest or chest, abdomen and pelvis meeting inclusion criteria and not meeting any exclusion criteria will be included in the study. The patient will be administered a low dose of intravenous contrast based on the study examination as described below.

CTA of the chest: 40 mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds.

CTA of the chest and abdomen or CTA of the chest, abdomen and pelvis: 50 mL of intravenous contrast (Omnipaque) at a rate 5mL/sec. A region of interest (ROI) to trigger the scan will be placed in the aortic arch. If scan is performed using high pitch helical mode, the scan delay will be increased by 2 seconds.

Following the examination, the primary investigator (PI) or team members will evaluate the images obtained with low contrast dose and each patient's prior CTA examination performed with routine contrast dose, 100mL at a rate of 4mL/sec. This will be done by quantitative and qualitative measures. For the quantitative portion, the PI or team members will place regions of interest on predetermined arterial locations to obtain measure the degree of opacification. For qualitative measurement, the images will be presented in a blind fashion to two thoracic trained board certified radiologists and a board certified interventional radiologist to determine the quality of the images based on a Likert numerical scale. Qualitative and quantitative data for the images obtained with low contrast dose and those for the prior CTA examinations performed with routine contrast dose will be compared. This data along with details of the scan protocol (dose, dose rate, scanning parameters etc.) and demographic data (such as sex, age and BMI at the time of examination) will be recorded. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02669784
Study type	Interventional
Source	Milton S. Hershey Medical Center
Contact
Status	Completed
Phase	N/A
Start date	February 2016
Completion date	November 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04149600` - Identification of Genetic Causes of Calcific Aortic Valve Disease
Enrolling by invitation	`NCT04035356` - HAART Annuloplasty Device Valve Repair Registry
Recruiting	`NCT02729064` - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose	Phase 1
Completed	`NCT02467062` - Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.	N/A
Completed	`NCT02283307` - Dual Energy CT Urography With Reduced Iodinated Contrast	N/A
Completed	`NCT01678261` - X-chromosome Inactivation, Epigenetics and the Transcriptome	N/A
Terminated	`NCT01055275` - Cook Iliac Branch Graft Post-market Registry	N/A
Completed	`NCT00615888` - Fast Track Management in Elective Open Infrarenal Aortic Aneurysm Repair	N/A
Completed	`NCT03510793` - Microcirculation and Anesthesia in Vascular Surgery
Completed	`NCT03207568` - RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)	N/A
Recruiting	`NCT05073991` - Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
Completed	`NCT02000544` - Clinical Evaluation of a Modular Extracorporeal Circulation Circuit	N/A
Not yet recruiting	`NCT01918969` - Reference Values of Circulating Endothelial Progenitor Cells	N/A
Not yet recruiting	`NCT01918982` - Circulating Endothelial Progenitor Cells and Aortic Aneurysm	N/A
Completed	`NCT01256372` - An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery	Phase 2
Recruiting	`NCT00661518` - PET/CT Imaging of Aneurysm Wall Inflammation	N/A
Completed	`NCT00094575` - Standard Open Surgery Versus Endovascular Repair of Abdominal Aortic Aneurysm (AAA)	Phase 4
Recruiting	`NCT04471909` - NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness	N/A
Recruiting	`NCT05603520` - Phenotyping Heterogeneity and Regionality of the Aorta
Completed	`NCT03727542` - Influence of Short AV Delay Permanent Pacing on Matrix Metalloproteinase Levels	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.